Please login to the form below
Novartis set to cut UK workforce
Novartis is consulting with staff at its Horsham plant on proposals to reduce the workforce by 550
Novartis is set to cut around 550 jobs as it restructures operations at its Horsham, UK, facility.
There are currently about 950 staff working at the site, with the number set to be reduced to around 400 over the next two years.
The company said the proposals are subject to an employee consultation and final board approval.
Sue Webb, general manager, UK & Ireland and country president, said: "Novartis is continuously evaluating its resource allocation to ensure that the organisation is highly flexible and able to proactively adapt to external challenges which best meet the needs of its customers.
"With significant changes in healthcare systems aimed to contain or cut cost, this critical assessment and the subsequent potential changes to the Novartis UK organisation are key to maintain significant investment in innovative drugs and our research efforts in the UK."
The site is shared by: Novartis Pharmaceuticals, Novartis Institutes for BioMedical Research (NIBR), and Novartis Consumer Health.
The news follows Pfizer's decision to close its facility in Kent, with the loss of 2,400 jobs.
Share
Related Hub content
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis
- Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children
- Havas Health & You appoints Alex Okada as chief creative officer of Havas Lynx Group
PMHub
Medscape Education Global
Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
